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Abstract
Objective: Mucositis is a serious disorder of the gastrointestinal tract that results from cancer chemotherapy. We
investigated the effects of increasing grape seed extract doses on the severity of chemotherapy in a rat model and its
coincident impact on chemotherapeutic effectiveness in colon cancer cells.
Design: Female Dark Agouti rats were gavaged with grape seed extract (400–1000 mg/kg) or water (day 3–11) and were
injected intraperitoneally with 5-Fluorouracil (150 mg/kg) or saline (control) on day 9 to induce mucositis. Daily metabolic
data were collected and rats were sacrificed on day 12. Intestinal tissues were collected for histological and
myeloperoxidase analyses. Caco-2 cell viability was examined in response to grape seed extract in combination with 5-
Fluorouracil by 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium bromide) assay.
Results: Compared with 5-Fluorouracil controls, grape seed extract (400–1000 mg/kg) significantly decreased the
histological damage score (P,0.05) in the jejunum. Grape seed extract (1000 mg/kg) increased jejunal crypt depth by 25%
(P,0.05) in 5-Fluorouracil treated rats compared to 5-Fluorouracil controls, and attenuated the 5-Fluorouracil -induced
reduction of mucosal thickness (25%, P,0.05). Grape seed extract (600 mg/kg) decreased myeloperoxidase activity by 55%
(P,0.01) compared to 5-Fluorouracil controls. Grape seed extract was more effective at ameliorating 5-Fluorouracil induced
intestinal injury, with effects most pronounced in the proximal jejunum. Grape seed extract (10–25 ug/mL) significantly
enhanced the growth-inhibitory effects of 5-Fluorouracil by 26% (P,0.05) in Caco-2 cells and was more potent than 5-
Fluorouracil at 50–100 mg/mL.
Conclusion: Grape seed extract may represent a new therapeutic option to decrease the symptoms of intestinal mucositis
while concurrently impacting on the viability of colon cancer cells.
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Introduction
Mucositis is a serious, debilitating consequence of cancer
therapy, which significantly reduces quality of life in cancer
patients [1]. Mucositis is a painful condition associated with
inflammation and ulceration of the gastrointestinal tract; most
commonly affecting the mucosa of the mouth (oral mucositis) and
small intestine (intestinal mucositis). Intestinal mucositis is charac-
terized by reduced enterocyte proliferation and increased
apoptotic rate of crypt cells, resulting in malabsorption and
disrupted barrier function [2,3]. Symptoms of mucositis include
intense pain, diarrhoea, nausea, vomiting and anorexia. Often
there is an increased risk of bacterial infection with associated
mortality and morbidity [1]. Sometimes, gastrointestinal toxicity
may lead to a reduction, or even termination, of the chemotherapy
regimen [4]. Due to this, the chemotherapy dose administered to
cancer patients often be sub-optimal; hence new regimens that
reduce side-effects, maintaining efficacy are sought. Current
mucositis treatments are largely ineffective as they target only
the symptoms, but not the pathogenesis of the condition [5]. Thus,
it is important to seek new alternative treatments which not only
target mucositis but also enhance chemotherapeutic action
without compromising the well-being of the patient. At present,
the optimal combination of agents which could enhance both
chemotherapeutic cytotoxicity against cancer cells and have
minimal impact on normal cells, has not yet been determined.
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85184
Grape seed extract (GSE) is widely consumed as a dietary
supplement on the basis of its potent anti-oxidant [6], anti-
inflammatory [7] and purported, anti-neoplastic [8] properties.
Procyanidins (PCs) are a class of polyphenolic compounds
composed of flavan-3-ol subunits (oligomers and polymers) [9].
PCs are widely found in other food sources such as tea, apples and
red wine and are believed to be the key bioactive constituents in
GSE [10,11]. Several studies have reported that the absorption
and bioavailability of PCs in the gut is dependent upon their
chemical structure and degree of polymerization [12]. PCs (degree
of polymerization = 7 or higher) are retained in the intestinal tract,
thereby increasing contact time with gut enterocytes to promote
intestinal health [10]. Studies examining GSE in combination with
5-Fluorouracil (5-FU) in normal animals are limited. In addition,
no studies have been published examining the combination of 5-
FU and GSE in colon cancer models.
Previously, we demonstrated in a preliminary study that GSE
(400 mg/kg) was able to reduce intestinal damage both in rat
models of intestinal mucositis [13] and ulcerative colitis [14].
However, the dose required to achieve maximal therapeutic
benefit, dose-responsiveness and safety of GSE remained unde-
fined. Accordingly, we investigated GSE across a range of doses
for its potential to optimally and safely reduce the severity of
intestinal mucositis in a rat model. Increasing doses of GSE further
prevented 5-FU-induced mucositis damage, and these treatments
were well tolerated by the animals as no metabolic changes were
observed compared to the healthy controls. In addition, we also
investigated the effects of the combination of GSE with 5-FU
chemotherapy on colonic neoplasia in an in vitro model compared
to the effectiveness of 5-FU alone. The combination of GSE and 5-
FU further enhanced toxicity in colon cancer cells.
Materials and Methods
Chemicals
Catechin, epicatechin, methanol, phloroglucinols, ascorbic acid
hexadecyltrimethylammonium bromide (HTAB), sodium bicar-
bonate and o-dianisidine were purchased from Sigma Chemical
Co. Ltd, St Louis, MO. Folin-ciocalteau reagent and 13C sucrose
were purchased from AnalaR, BDH, MERCK, Pty. Ltd.,
Australia. Tissue culture solutions include Dulbecco’s Modified
Eagle’s Minimum Essential Medium (DMEM), fetal calf serum
(FCS), antibiotics (penicillin, gentamicin and streptomycin),
Dulbecco’s Phosphate Buffered Saline, dimethyl sulfoxide
(DMSO) and 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium
bromide) (MTT) were purchased from Gibco BRL, Life
Tehnologies Pty Ltd, Australia. The chemotherapy drugs, 5-
Fluorouracil (5-FU) were purchased from MaynePharma Pty.
Ltd., Australia).
Grape seed extract (GSE) preparation
Grape seed extract was kindly donated by Tarac Techologies
(North Adelaide, South Australia, batch no: 02VIN03) and stored
in an air-tight, light-resistant pack until being dissolved in distilled
water prior to use. The GSE was derived from condensed tannin
made from Australian white wine marc (residual skins and seeds
from winemaking). The nutrition profile of GSE is listed in
Table 1. The GSE utilized in the current study was obtained from
the same source with the same batch number to that described by
Cheah et al [13]. The polyphenolic content was measured
previously by Folin-ciocalteau assay [13], and the chemical profile
was quantified by phloroglucinolysis described below.
Folin-ciocalteau assay
The total phenolic content of GSE was previously quantified by
Folin-ciocalteau assay [13]. Briefly, GSE samples were added in
triplicate to non-sterile 96 well plates and incubated with Folin-
ciocalteu reagent for 5 min. Sodium bicarbonate solution (7.5%
w/v) was added and further incubated for 4 h in the dark. The
plate was read at 740 nm by a spectrometer (MultiskanH
Spectrum, Therma Electron Corporation, Vantaa, Finland) using
Skanit software 2.2. Catechin standards were prepared from
1 mg/mL stock (1/2 serial dilutions) and used to generate a
calibration curve. Data were analysed using GraphPad Prism
version 4.0 for windowsH (GraphPad Software, San Diego, CA,
USA) and expressed in mg/mL catechin equivalents.
Quantification of procyanidins (PCs) in GSE by
phloroglucinolysis
The procyanidin profile of GSE was characterized by phlor-
oglucinolysis which determines the subunit composition, mean
degree of polymerization (mDP) and galloylation of PCs.
Phloroglucinolysis was performed according to a previously
described method [15]. GSE was dissolved in methanol (10 mg/
mL, v/v) and 25 mL of GSE was added to an equal volume of
phloroglucinol solution (0.2 N HCL in methanol, 100 g/L of
phloroglucinol and 20 g/L of ascorbic acid). The phloroglucino-
lysis reaction was carried out at 50uC for 25 min and analyzed by
reverse phase-high pressure liquid chromatography (RP-HPLC)
using (2)-epicatechin as quantitative standard [15].
Ethic Statements
This study followed the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes and was approved by
both the Animal Care and Ethics Committees of the Children,
Youth and Women’s Health Service and the University of
Adelaide (AE:777-3-2011).
Animal studies
Female Dark Agouti rats (100–140 g, n= 64) were housed in
individual metabolic cages (Tecniplast, Exton, PA, USA) in a
temperature-controlled room (22uC) with a light-dark cycle of
12 h. Rats were given ad libitum access to water and food (18%
casein-based diet) [16] in the Animal Care Facility of the Children,
Youth and Women’s Health Service, North Adelaide, South
Australia.
Table 1. Nutritional and phenolic content of grape seed
extract (GSE).










1The nutrition profile of GSE is represented as quantity/100 g.
2The phenolic content was obtained from Folin-ciocalteau (FC) assays.
doi:10.1371/journal.pone.0085184.t001
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Rats were randomly allocated to 8 groups (n = 8): Water+Saline
injection; GSE 400 mg/kg+Saline injection; GSE 600 mg/kg+Sa-
line injection; GSE 1000 mg/kg+Saline injection; Water+5-FU
injection (5-Fluorouracil: 150 mg/kg); GSE 400 mg/kg+5-FU
injection; GSE 600 mg/kg+5-FU injection; and GSE 1000 mg/
kg+5-FU injection. Rats were acclimatized in metabolism cages
from day 0–2 and then gavaged with 1 mL GSE dissolved in water
(400 mg/kg, 600 mg/kg or 1000 mg/kg) or water from day 3–11.
At day 9, all rats were intraperitoneally injected with either 5-FU
or saline (controls). Daily measurements of body weight, food and
water intake, and urine and faecal output were recorded. Rats
were sacrificed by CO2 asphyxiation followed by cervical
dislocation on day 12. All visceral organs were weighed and
discarded. The lengths and weights of the gastrointestinal organs
(duodenum, small intestine and colon) were recorded. Represen-
tative samples (2 cm) of gastrointestinal organs were collected and
fixed in 10% buffered formalin for histological analyses, while four
cm samples were snap frozen in liquid nitrogen and stored at
280uC for biochemical analysis.
13C-sucrose breath test (SBT)
The SBT is an indirect measure of intestinal sucrase activity and
was performed according to the method described by Tooley et al.
[17] In brief, rats were oro-gastrically gavaged with 1 mL of
sucrose solution containing 13C (250 mg/kg) and breath samples
were collected at 15 min intervals for 120 min. Breath samples
were analyzed for 13CO2 content by isotope ratio mass spectrom-
etry (IRMS) equipped with a V410 data collection system (Europa
Scientific, ABCA 20/20, Crewe, United Kingdom). The data were
expressed as percentage cumulative dose at 90 min (%CD90) by
calculating the change in breath 13CO2 levels from baseline for
each time point of breath collection throughout the period of
interval sampling. SBT determinations were performed at day 3
(before GSE treatment), day 9 (before 5-FU injection) and day 12
(before kill).
Myeloperoxidase (MPO) assay
Small intestinal tissue samples (4 cm) of jejunum, junction of
jejunum and ileum (JI) and ileum were thawed on ice and
homogenized with 1.5 mL of phosphate buffer (10 mM, pH 6.1)
for 60 seconds until the solution was homogenous. The homog-
enates were kept frozen at 280uC until required.
MPO is an enzyme present in the intracellular granules of
neutrophils, acting as an acute inflammation marker. The level of
MPO in the small intestine was determined by a slight
modification of the assay described by Krawisz et al. [18] Tissue
homogenates were thawed on ice and centrifuged at 13000 g for
13 min. The supernatant was discarded and cell pellets were re-
suspended in hexadecyltrimethyl ammonium bromide (0.5%,
pH 6.0). The samples were vortexed for 2 min and further
centrifuged at 13000 g for 3 min. Supernatants were reacted with
o-dianisidine and absorbance measured at 450 nm at 1 min
intervals for a period of 15 min using a microplate reader (Sunrise
Microplate Reader, Tecan Austria GmbH, Grodig, Austria).
MPO activity was expressed as units MPO activity per gram of
tissue.
Histological analyses
Gut tissue samples (2 cm) were embedded in paraffin wax and
4 mm sections were stained with haemotoxylin and eosin. The
overall histological disease severity score (ODS) of intestinal
sections was rated semi-quantitatively (0–3) based on 11 indepen-
dent histological criteria according to a protocol described by
Howarth et al. [19] Villus heights and crypt depths (40 villi and 40
crypts per section) were determined in the small intestinal sections
including jejunum, junction of jejunum and ileum (JI) and ileum as
described in Howarth et al. [19] The combined measurement of
villus heights and crypt depths provided an approximation of total
mucosal thickness in each small intestinal specimen. All micro-
scope-based analyses were performed in a blinded fashion using a
light microscope (Nikon, ProgResHCS, Tokyo, Japan) and image
ProPlus software version 5.1 (Media Cybernetics, Silver Spring
MD, USA).
Cell Culture
The human colon cancer cell line, Caco-2 was obtained from
the American Type Culture Collection (ATCC, Manassas, USA).
Caco-2 cells were maintained at 37uC in a humidified incubator
with 5% CO2 – 95% air, and 90% relative humidity in Dulbecco’s
Table 2. The chemical profiles of grape seed extract characterized by phloroglucinolysis.
MC1 mDP2 galloylation MM
3 Terminal subunits4 Extension subunits4
(%) (%) (subunit) C E ECG C-P E-P ECG-P
GSE 23.8 5.9 19 1871 20.1 14.0 65.9 8.9 53.0 38.1
1Mass conversion based on % recovery of procyanidin by phloroglucinolysis based on the gravimetric mass.
2Mean degree of polymerization.
3Estimated molecular mass based on subunit composition from phloroglucinolysis.
4Percent composition of terminal and extension subunits (in moles) with the following subunit abbreviations: (-P), phloroglucinol adduct of extension subunit; C, (+)-
catechin; EC, (2)-epicatechin; ECG, (2)-epicatechin-3-O-gallate.
doi:10.1371/journal.pone.0085184.t002
Table 3. Effects of increasing doses of grape seed extract
(GSE; mg/kg) on cumulative body weight change, food and
water intake, urine and faecal output in saline-injected rats
over day 3–9.
Day 3–9
Water GSE 400 GSE 600 GSE 1000
(n=16) (n=16) (n=16) (n=16)
Body Weight Change
(g)
12.060.9 11.760.7 10.561.3 11.160.8
Water Intake (mL) 174.267.9 175.566.8 171.667.9 185.1610.1
Food Intake (g) 66.260.8 63.861.1 62.461.6 62.260.9
Urine Output (mL) 117.866.7 115.264.9 112.765.9 127.868.4
Faecal Output (g) 8.260.1 8.560.3 8.860.3 9.160.3
Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0085184.t003
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Modified Eagle’s Minimum Essential Medium (DMEM) supple-
mented with 10% (v/v) fetal calf serum (FCS) and 1% antibiotics
(penicillin, gentamicin and streptomycin) (v/v). The cells were
grown in 75 cm2 vented tissue culture flasks, culture medium was
changed twice a week and cells were passaged when they were 80–
90% confluent.
Cell viability
The inhibition of Caco-2 cells viability was determined by 3-
(4,5-Dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium bromide)
(MTT) assay according to a previously described method by
Huynh-Delerme et al. [20] Cells (56103 cells/well) were seeded on
96-well tissue culture plates for 48 hrs to allow attachment. GSE
was prepared in dimethyl sulfoxide (DMSO) and diluted with
DMEM and further filter-sterilized through a 0.22 mM filter
(Millipore, South Australia, Australia). In all experiments, the
concentration of DMSO in control and treated samples was less
than 0.025%. After 48 h, culture medium was replaced with
serum free media containing GSE at different concentrations (mg/
mL) and 5-FU (mM) and further incubated for either 24 or 48 h.
MTT solution was prepared in Dulbecco’s Phosphate Buffered
Saline (1 mg/mL) and sterile-filtered to remove any biological
contaminants. Next, 50 mL of MTT solution was added to each
well and further incubated at 37uC for 4 h. Medium was replaced
with 100 mL of DMSO to extract the formazan product. Plates
were placed on a shaking incubator for 15 min and read by
spectrometer at 570 nm. Data were expressed as number of viable
cells as a percentage of control cells treated with serum free
medium only.
Statistical analyses
Statistical analyses were conducted using PASW 18 (SPSS, Inc.,
Chicago, IL, USA) and XLSTAT version 2011.4.02 (Addinsoft
SARL, France). All parametric data including bodyweight, daily
metabolic data, SBT, MPO, villus height and crypt depth and cell
viability were compared using one-way analysis of variance
(ANOVA) with a Tukey’s post-hoc test. The overall disease severity
score (ODS) was compared by a Kruskal-Wallis test with a Mann
Table 4. Effects of increasing doses of grape seed extract (GSE; mg/kg) on cumulative body weight change, food and water intake,
urine and faecal output in saline-injected rats and in 5-Fluorouracil (5-FU) injected rats from day 10–12.
Day 10–12
Water+Saline Water+5-FU GSE 400+5-FU GSE 600+5-FU GSE 1000+5-FU
(n=8) (n =8) (n =8) (n=8) (n=8)
Body Weight Change (g) 24.361.1 28.960.8* 29.860.5** 29.460.9** 29.860.1**
Water Intake (mL) 73.362.0 109.4610.8* 100.065.3 89.8612.2 113.4610.7*
Food Intake (g) 28.760.8 13.860.9*** 13.860.8*** 12.761.4*** 13.361.0***
Urine Output (mL) 56.362.6 85.866.4* 87.364.5* 80.067.0* 89.8611.0*
Faecal Output (g) 3.660.2 2.360.3** 2.860.2 3.560.3## 3.360.1#





##P,0.01 compared to Water+5-FU.
doi:10.1371/journal.pone.0085184.t004
Table 5. Effect of increasing doses of grape seed extract (GSE; mg/kg) on organ weights of female Dark Agouti rats 72 h after 5-
Fluorouracil (5-FU) or saline injection.





(n =8) (n=8) (n=8) (n =8) (n =8) (n=8) (n =8) (n =8)
Heart 39766 39366 40668 40268 40567 414616 40866 40366
Lung 61168 593610 625618 657638 721649 711640 663647 580658
Liver 3111657 3008643 3072663 3114645 33706144 3334685 3353673 3311641
Kidneys 832626 816615 815618 857613 874620 896621 880613 891619
Thymus 181618 148617 178613 183614 88618*** 8667*** 91615*** 6968***
Spleen 19865 20565 19368 20564 15966** 15565** 150613*** 15363***
Stomach 600610 630610 640610 680610* 590630 650610 650620 680620*
Caecum 370610 360610 410640 400610 470640 490650 440630 440630
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Whitney U-test to identify significance between groups. Data were
considered significant at P,0.05.
Results
Characterization of procyanidins by phloroglucinolysis
GSE had low mass conversion (23.8% w/w), mDP (5.9) and
molecular mass (1871 g/mol), as measured by phloroglucinolysis
(Table 2). The PC terminal subunits in GSE were mostly
dominated by (2)-epicatechin-3-O-gallate.
Daily metabolic parameters and bodyweight
Oral administration of GSE (400, 600 or 1000 mg/kg) between
days 3 and 9 did not significantly affect body weight, food or water
intake and urine or faecal output compared to rats receiving water
(Table 3). 5-FU injection significantly increased water intake and
urine output and reduced body weight, food intake and faecal
output compared to rats receiving saline injection between days 10
and 12 (Table 4). GSE 600 and 1000 mg/kg in 5-FU treated rats
significantly returned faecal output (P,0.01), back towards the
values for normal saline-injected control rats.
Visceral organs
5-FU injection significantly reduced thymus weight by 51%
(P,0.001) and spleen weight by 20% (P,0.01) compared to
saline-injected rats. Whilst GSE did not prevent any of the 5-FU-
induced changes in thymus and spleen weight, none of the GSE
doses tested impacted negatively on visceral organ weights
(Table 5) nor gastrointestinal organ weights and lengths (Table 6)
in healthy animals. However, GSE 1000 mg/kg significantly
increased stomach weight by 13% (P,0.05) compared to normal
controls.
Sucrose breath test (SBT)
5-FU injection significantly (P,0.001) decreased the SBT
(%CD90) by 70% compared to values in water+saline treated
rats, indirectly indicating 5-FU injection had disrupted brush
border sucrase activity (Figure 1). There were no significant
differences in %CD90 among any of the 5-FU treated rats
receiving GSE compared to 5-FU treated-control rats. In addition,
no significant differences in %CD90 were observed between GSE
and water treatment, implying none of the GSE doses had
demonstrably impacted on brush border sucrase activity in healthy
rats (Figure 1).
Myeloperoxidase activity (MPO)
Following 5-FU injection, there was a significant (P,0.001)
increase in MPO activity in the proximal jejunum, junction of
jejunum and ileum (JI) and ileum of water+5-FU treated rats
(1092%, 357% and 297% respectively) compared to water+saline
treatment (Figure 2). GSE 600 mg/kg significantly (P,0.01)
reduced MPO activity by 55% in the JI compared to water+5-
FU treated rats (Figure 2B). There was no significant difference in
MPO activity between GSE and water treatment in healthy rats
(Figure 2), indicating that GSE administration did not affect MPO
activity in healthy animals.
Overall disease severity scores
Administration of 5-FU significantly increased disease severity
score in the proximal jejunum when assessed by the semi-
quantitative histological severity score analysis (Figure 3 and 4). 5-
FU controls attained the highest damage score (median score = 30)
and were significantly greater than water+saline treated rats
(median score = 1, P,0.01). GSE treatment significantly reduced
Figure 1. Effects of GSE (mg/kg) on small intestinal sucrase
activity assessed by the sucrose breath test on day 12 (72 h
after 5-FU or Saline injection). Data expressed as mean (%CD90) 6
SEM. *** indicates P,0.001 compared to Water+Saline.
doi:10.1371/journal.pone.0085184.g001
Table 6. Effects of increasing grape seed extract (GSE; mg/kg) doses on gastrointestinal organ weights and lengths of female Dark
















(n=8) (n=8) (n=8) (n=8) (n =8) (n=8) (n =8) (n=8)
Duodenum
Weight (g/kg) 2061 1861 2061 2261 2161 2161 2061 2462
Length (cm) 506628 540630 520620 560610 530610 520620 520620 530630
Jejunum+Ileum
Weight (g/kg) 19965 21365 20465 22865 19363 19365 19867 208064
Length (cm) 71006140 72506110 70406160 73806190 68506110 6840690 70906120 6860660
Colon
Weight (g/kg) 5362 5362 5262 5662 6463 5562 6366 6064
Length (cm) 1180640 1130640 1090650 1210650 1020640 1050640 1140640 1150620
Gastrointestinal organ weights are expressed in (wt g/kg bwt)6100% and lengths are expressed in (cm). Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0085184.t006
Grape Seed Extracts as Adjunct to Combat Mucositis
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e85184
disease severity score in 5-FU treated rats in a dose-responsive
manner (GSE 400=21 (15.5–25.5), P,0.01; GSE 600= 15.75 (9–
24), P,0.01; and GSE 1000= 11.75 (7–19), P,0.01) compared to
5-FU controls. No significant difference in disease severity score
was observed between GSE and water treated rats receiving saline
injection (Figure 3), indicating that GSE had not disrupted
intestinal integrity in healthy animals.
Villus height, crypt depth and mucosal thickness
5-FU injection resulted in shortening of the villi in the jejunum
(38%, P,0.001), JI (39%, P,0.001) and ileum (26%, P,0.01)
compared to water controls (Figure 5). 5-FU injection also reduced
crypt depth in the jejunum (38%, P,0.001), JI (23%, P,0.05) and
ileum (15%, P,0.05). In the jejunum, GSE treatments tended to
dose-responsively improve villus height and crypt depth, although
only GSE at a dose of 1000 mg/kg significantly (P,0.05)
increased crypt depth compared to 5-FU controls (Figure 5A).
Importantly, none of the GSE treatments impacted negatively on
villus height and crypt depth in healthy animals. 5-FU injection
significantly reduced mucosal thickness in the jejunum (38%,
P,0.001), JI (45%, P,0.001) and ileum (29%, P,0.01) compared
to water controls (Figure 6). GSE treatments tended to dose-
responsively increase mucosal thickness in the jejunum, although
only GSE 1000 mg/kg significantly increased mucosal thickness
(25%, P,0.05) compared to 5-FU controls (Figure 6A).
Effects of 5-FU on viability of Caco-2 cells
The dose responses of 5-FU (0–100,000 mM) on Caco-2 cells for
24 h and 48 h are illustrated in Figure 7. 5-FU doses were also
tested at 72 h (Data not shown). The cell viability of Caco-2 cells
was inhibited by 5-FU in a time- and dose-dependent manner. At
24 h, 5-FU at 100 mM significantly reduced viability in Caco-2
cells to 88% (P,0.05) of control values and a further reduction of
cell viability was observed to 70% (P,0.05) of control values at
48 h. A 100 mM concentration of 5-FU was selected for the next
experiment because this dose was able to reduce Caco-2 cell
viability (70–85%) reflecting gastrointestinal toxicity commonly
observed in cancer patients following chemotherapy.
Effects of GSE and 5-FU on Caco-2 cell viability
In order to establish the cytotoxicity of GSE on Caco-2 cells,
GSE (10–100 mg/mL) was applied to cells for either 24 or 48 h
(Figure 8). GSE treatment inhibited cell viability in a dose- and
time-dependent manner. GSE treatments significantly (P,0.05)
reduced cell viability (IC50 = 50.24 mg/mL) at 24 h and became
more toxic to the Caco-2 cells at 48 h (IC50 = 37.84 mg/mL).
When the cells were exposed to the combination of GSE (10–
100 mg/mL) and 5-FU (100 mM), greater numbers of dead cells
were evident compared to cells exposed to 5-FU alone (Figure 8).
At 24 h, 5-FU significantly reduced cell viability to 84% (P,0.05)
of control values. Interestingly, when Caco-2 cells were exposed to
the combination of GSE and 5-FU, the growth inhibitory effects of
Figure 3. Effects of GSE (mg/kg) on histological severity scores
in the jejunum 72 h after either saline or 5-FU injection. The
severity scores were rated based on 11 parameters on different layers of
intestinal tissues based on previously described protocol Howarth et al.
[19] The box plots represent the range of disease severity score and the
horizontal lines represent the median disease severity score. ** indicates
P,0.01 compared to Water+Saline. ## indicates P,0.01 compared to
Water+5-FU.
doi:10.1371/journal.pone.0085184.g003
Figure 2. Effects of GSE (mg/kg) on Myeloperoxidase (MPO)
activity in the jejunum (A), JI (B) and ileum (C) 72 h after either
saline or 5-FU injection. Data are expressed as mean (MPO units/g
tissue) 6 SEM. * indicates P,0.05, ** indicates P,0.01 and *** indicates
P,0.001 compared to rats receiving water and saline injection. ##
indicates P,0.01 compared to rats receiving water and 5-FU injection.
doi:10.1371/journal.pone.0085184.g002
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5-FU were significantly enhanced by 26% (GSE=25 mg/mL;
P,0.05; combined treatment vs. both agents alone) at 24 h. GSE
at higher doses (50–100 mg/mL) exerted greater growth inhibition
compared to 5-FU alone. At 24 h, GSE induced significant growth
inhibitory effects on Caco-2 cells (GSE 50= 33% and GSE
100= 27%; P,0.05) compared to 5-FU control (84% of control
value) (Figure 8A). In addition, GSE alone significantly (P,0.05)
decreased the viability of Caco-2 cells (GSE 50=31% and GSE
100= 29%; P,0.05) compared to 5-FU control (64% of control
value) at 48 h (Figure 8B).
Discussion
The present study represents the first report of GSE dose-
responsively reducing severity of mucositis. Our findings suggest
that higher doses of GSE are more effective at reducing the
severity indicators of intestinal mucositis in rats and that these
GSE-induced effects are largely dose-dependent and more evident
in the proximal jejunum compared to the distal small intestine.
Injection of 5-FU impacts on the small intestine to a greater
extent than the large intestine, presumably due to the greater cell
turnover rate in the more proximal regions of the gut [3]. Our
Figure 4. Representative photomicrographs of the proximal jejunum sections stained with haematoxylin and eosin in Water+Saline
(A), GSE 400 mg/kg+Saline (B), GSE 600 mg/kg+Saline (C), GSE 1000 mg/kg+Saline (D), Water+5-FU (E), GSE 400 mg/kg+5-FU (F),
GSE 600 mg/kg+5-FU (G) and GSE 1000 mg/kg+5-FU (H). (Original magnification 406.)
doi:10.1371/journal.pone.0085184.g004
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results are in agreement with previous studies [18,19,21], in which
the 5-FU mucositis model resulted in severe intestinal injury 72 h
after the induction of mucositis. This damage was characterized by
a reduction of intestinal brush border enzyme activities [21],
increased neutrophil infiltration [22], increased disease severity
score [23] and decreased mucosal thickness [13]. Consistent with
earlier studies [13], blunting of the villi and disorganization of
crypts (location of stem cells) were the primary events associated
with severe mucositis. The jejunum is the maximal site of injury
induced by chemotherapy and the impact becomes less pro-
nounced in the more distal regions of the small intestine [13]. This
was demonstrated in the current study in which less injury was
observed in terms of MPO activity (neutrophil infiltration), villus
height and mucosal thickness at the distal end of the small intestine
The bioavailability of PCs in the gut system has been well
documented in other studies [24]. The unique polymerized
structure of PCs inhibits absorption across the small intestine, as
they adhere to the gut mucosa [25]. Tsang et al. [26] detected
larger forms of PCs in the small intestine of rats up to 12 h after
ingestion. Thus, an accumulation of relatively high PC concen-
trations can occur in the gut lumen to protect the intestinal barrier.
In the current study, higher doses of GSE (1000 mg/kg) were
effective at maintaining crypt depth and mucosal thickness in the
jejunal region, with most values approaching the values of healthy
Figure 5. Effects of GSE (mg/kg) on villus height and crypt
depth in the jejunum (A), JI (B) and Ileum (C) 72 h after either
saline or 5-FU injection. Data are expressed as mean (mm) 6 SEM. *
indicates P,0.05, ** indicates P,0.01 and *** indicates P,0.001
compare to Water+Saline. # indicates P,0.05 compared to Water+5-
FU.
doi:10.1371/journal.pone.0085184.g005
Figure 6. Effects of GSE (mg/kg) on mucosal thickness in the
jejunum(A), JI (B) and Ileum (C) 72 h after either saline or 5-FU
injection. Data are expressed as mean (mm)6 SEM. * indicates P,0.05,
** indicates P,0.01 and *** indicates P,0.001. # indicates P,0.05
compared to Water+5-FU.
doi:10.1371/journal.pone.0085184.g006
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controls. Furthermore, the current study also showed improve-
ment of fecal output (less severe diarrhoea) in chemotherapy-
treated rats receiving the higher dose of GSE (600 mg/kg and
1000 mg/kg), suggesting reduced disruption of the mucosal lining
of the small intestine.
Although GSE in the current study was more effective in the
jejunum, the site of major intestinal injury, bioactivity was reduced
in the distal small intestine. This may have been due to degraded
bioactive components reaching the distal region of the small
intestine [27,28]. The cleavage, absorption and metabolism of
GSE is important to identify the fate of bioactive compounds in
GSE. In future studies it will be necessary to identify the form, size
and bioactivity of procyanidins from GSE responsible for
promoting intestinal health using in vitro and in vivo models of
intestinal absorption. Additionally, future studies could examine
protection of GSE, possibly by microencapsulation, or via
suppository application, to better target GSE and improve its
bioavailability in the more distal regions of the bowel. Due to the
complexity of GSE content, it would be difficult to determine
which factors are responsible for the observed bioactivity. For this
reason, GSE, rather than alternative protein source such as bovine
serum was used as its own control. Administration of GSE on
normal animals allowed more precise comparison with GSE-
treated rats receiving 5-FU chemotherapy.
Interest in GSE has been primarily due to its high antioxidant
content. GSE is a more potent radical scavenger than other known
anti-oxidants such as vitamin C and E [29]. In the present study,
the partial reduction in acute inflammation by GSE, as indicated
by the decrease of MPO activity, and reduction in lymphocyte
infiltration recorded by the disease severity score analysis, could
strengthen the potential role of GSE as a potent anti-oxidant and
anti-inflammatory agent. A number of studies have described GSE
as an anti-inflammatory agent. For example, GSE has been
reported to reduce the expression of pro-inflammatory cytokines
(TNF-a and IL-6) in mesenteric lymph nodes [30], rat plasma [31]
and carrageenan-induced paw edema in rats [32]. The reduction
of these activities may represent a consequence of GSE and its
ability to prevent NF-kB activation and subsequently reduce the
activation of nitric oxide and pro-inflammatory cytokines. Thus,
inhibition of NF-kB activation may have been a possible
mechanism by which GSE reduced mucosal injury and hence
mucositis severity, in the current study. Other biomarkers such as
inflammatory cytokines in tissue and blood could be measured in
future studies to quantify GSE effects on the systemic and mucosal
immune system.
PC rich food has been reported to be both beneficial and
detrimental to human health due to its ability to interact with
proteins (enzymes, toxins, hormones) [10,33]. The current study
provides important information on the safety of GSE usage. Oral
administration of GSE (400 mg/kg, 600 mg/kg and 1000 mg/kg)
for nine days did not induce any deleterious side-effects in healthy
animals. The increased of stomach weight in GSE treated rats
might be due to indigestible of GSE PCs deposited in the stomach.
GSE did not impact negatively on daily metabolic parameters, nor
induce any side-effects in the small intestine. Moreover, the
sucrose breath test indicated that GSE did not affect small
intestinal brush border enzyme activity. These data concur with
other studies [34] in which rats ingesting up to 2 g/kg of GSE
showed no abnormal metabolic findings or toxicological effects. In
the current study, GSE (1000 mg/kg) significantly increased
stomach weight in healthy rats. This finding has not been reported
previously [35], but could be a reflection of differing rat strains
between studies. Thus, histological analyses on rat stomach should
be conducted in future studies.
The promising effects of GSE in the mucositis rat model
provided the impetus to further investigate its potential impact on
the effectiveness of chemotherapy against transformed colono-
cytes. Recently, various strategies have been developed to counter
the development of mucositis (reduced gastrointestinal toxicity) or
to enhance the chemotherapeutic activity of 5-FU. To date, a
number of strategies to enhance 5-FU efficacy on colon cancer
have been investigated although none are clinically available.
These include omega 3-fatty acid [36], chloroquine [37], violecin
Figure 7. Viability of Caco-2 cells treated with 5-FU for either
24 h or 48 h, assessed by MTT assay. Data are expressed as
percent of cell viability relative to viability of untreated controls. Data
are presented as means 6 SEM of 2–3 independent experiments. Bar
data not sharing the same letter are significantly different P,0.05.
doi:10.1371/journal.pone.0085184.g007
Figure 8. Viability of Caco-2 cells either treated with GSE alone
(mg/mL) or GSE (mg/mL)+5-FU (100 mM) for either 24 h (A) or
48 h (B). Data are expressed as percent of cell viability relative to
untreated controls. Data are presented as means 6 SEM of 4
independent experiments. Bar data not sharing the same letters are
significantly different P,0.05.
doi:10.1371/journal.pone.0085184.g008
Grape Seed Extracts as Adjunct to Combat Mucositis
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e85184
[38] and ginseng [39] which have been reported to effectively
improve 5-FU efficiency at killing cancer cells in vitro compared to
the chemotherapy agent acting independently. In the current
study, the effects of GSE and 5-FU on Caco-2 cell viability were
examined at 24 h and 48 h. This was because 5-FU (100 uM)
significantly reduced cell viability to 70–85%, reflecting gastroin-
testinal toxicity in cancer patients. Moreover, longer time exposure
(24–48 h) of cancer cells to both GSE and 5-FU resulted in a
further reduction in cell viability. However, the differences
between treatments remained relatively unchanged even up to
72 h (data not shown). Importantly, GSE acted synergistically with
5-FU to inhibit Caco-2 cell proliferation.
GSE may act as a potent chemotherapeutic agent as it has been
demonstrated to exert selective cytotoxicity against tumour cells
compared to normal cells [40,41]. It has been suggested that GSE
induces growth inhibition in cancer cells via induction of cell cycle
arrest which eventually leads to the induction of caspase-
dependent apoptosis [8] and disruption of the mitochondrial
membrane [42]. Moreover, the current study demonstrated that
GSE alone at higher concentration, tended to induce greater
growth inhibitory effects on Caco-2 cells compared to 5-FU alone.
Thus, the current data support GSE as a promising anti-neoplastic
adjunct to cancer treatment. Future in vitro studies including
invasion, proliferation and growth analysis should be performed to
identify the phenotypic changes of colon cancer cells after GSE
treatment.
Although the current in vivo study revealed that GSE only
minimally improved parameters of intestinal mucositis (disease
severity score), future studies could examine the efficacy of higher
doses of GSE or alternatively more highly purified PC compounds.
Chemotherapy is likely to progress to a chronic condition. Future
studies should investigate GSE effects in rat models over
protracted periods of several weeks and months. The promising
findings of GSE in the in vitro model also support further studies
into the identification of bioactive components of GSE responsible
for these effects. The present study was conducted using female
Dark Agouti rats which can be manipulated to develop breast
cancer [43]. Such studies would facilitate further investigations
into GSE and its potential to modify tumour growth. The colon
cancer cell line was selected on the basis that it could be translated
later to an animal model of colon cancer. The current work
represents the synergistic effect of GSE and 5-FU at partially
preventing mucositis, whilst reducing Caco-2 cells viability. This
will allow us to further investigate GSE for its potential to modify
tumour growth with 5-FU by determining its effects on tumour
growth such as that induced by azoxymethane in rat model [44].
In conclusion, the current investigation provides the first
evidence for GSE to reduce the severity of intestinal mucositis in
a dose-responsive manner while enhancing the impact of 5-FU
chemotherapy on colon cancer cells. Dietary GSE could be a
promising adjunctive approach for combating intestinal mucositis
while concurrently potentiating the impact of conventional
chemotherapy for colon cancer.
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